Cutting edge: Physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo

Journal of Immunology

Volumn 173, Issue 1, 2004, Pages 21-24

  Lukashev, Dmitriy ^a   Ohta, Akio ^a   Apasov, Sergey ^a   Chen, Jiang Fan ^b   Sitkovsky, Michail ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE A2A RECEPTOR; CYTOKINE; G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; ATTENUATION; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HYPOXIA; IMMUNE DEFICIENCY; IMMUNE MEDIATED INJURY; IMMUNOCOMPETENT CELL; IN VIVO STUDY; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; SOLID TUMOR; TISSUE PROTECTION;

EID: 2942754121     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.1.21     Document Type: Article

References (26)

1. Ohta, A., and M. Sitkovsky. 2001. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414:916.
2. Sitkovsky, M., D. Lukashev, S. Apasov, H. Kojima, M. Koshiba, C. Caldwell, A. Ohta, and M. Thiel. 2004. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu. Rev. Immunol. 22:657.
3. Decking, U. K., G. Schlieper, K. Kroll, and J. Schrader. 1997. Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Circ. Res. 81:154.
4. Ledoux, S., I. Runembert, K. Koumanov, J. B. Michel, G. Trugnan, and G. Friedlander. 2003. Hypoxia enhances ecto-5′-nucleotidase activity and cell surface expression in endothelial cells. Circ. Res. 92:848.
5. Day, Y. J., M. A. Marshall, L. Huang, M. J. McDuffie, M. D. Okusa, and J. Linden. 2004. Protection from ischemic liver injury by activation of A2A adenosine receptors during reperfusion: inhibition of chemokine induction. Am. J. Physiol. 286:G285.
6. Day, Y. J., L. Huang, M. J. McDuffie, D. L. Rosin, H. Ye, J. F. Chen, M. A. Schwarzschild, J. S. Fink, J. Linden, and M. D. Okusa. 2003. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J. Clin. Invest. 112:883.
7. Bourne, H. R., L. M. Lichtenstein, K. L. Melmon, C. S. Henney, Y. Weinstein, and G. M. Shearer. 1974. Modulation of inflammation and immunity by cyclic AMP. Science 184.
8. Kammer, G. M. 1988. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol. Today 9:222.
9. Weissmann, G., P. Dukor, and R. B. Zurier. 1971. Effect of cyclic AMP on release of lysosomal enzymes from phagocytes. Nat. New Biol. 231:131.
10. Neumann, M., T. Grieshammer, S. Chuvpilo, B. Kneitz, M. Lohoff, A. Schimpl, B. R. Franza, and E. Serfling. 1995. RelA/p65 is a molecular target for the immunosuppressive action of protein kinase A. EMBO J. 14:1991.
11. Delgado, M., and D. Ganea. 1999. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor κB and Ets activation. J. Biol. Chem. 274:31930.
12. Chen, J.-F., Z. Huang, J. Ma, J. Zhu, R. Moratalla, D. Standaert, M. A. Moskowitz, J. S. Fink, and M. A. Schwartzschild. 1999. A2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. 19:9192.
13. Apasov, S. G., J.-F. Chen, P. T. Smith, M. A. Schwarzschild, J. S. Fink, and M. V. Sitkovsky. 2000. Study of A2A adenosine receptor gene-deficient mice reveals that adenosine analogue CGS 21680 possesses no A2A receptor-unrelated lymphotoxicity. Br. J. Pharmacol. 131:43.
14. 3H]ZM241385: an antagonist radioligand for adenosine A2A receptors in rat brain. Eur. J. Pharmacol. 411:205.
15. Poltorak, A., X. He, I. Smirnova, M. Y. Liu, C. V. Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4gene. Science 282:2085.
16. Wagner, H. 1999. Bacteria/CpG DNA activates immune cells to signal infectious danger. Adv. Immunol. 73:329.
17. Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408:740.
18. Melief, C. J., S. H. Van Der Burg, R. E. Toes, F. Ossendorp, and R. Offringa. 2002. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol Rev. 188:177.
19. + T cell responses and protection against Leishmania major infection. J. Exp. Med. 195:1565.
20. Lukashev, D. E., P. T. Smith, C. C. Caldwell, A. Ohta, S. G. Apasov, and M. V. Sitkovsky. 2003. Analysis of A2a receptor-deficient mice reveals no significant compensatory increases in expression of A2b, A1 and A3 adenosine receptors in lymphoid organs. Biochem. Pharmacol. 65:2081.
21. Karin, M., and Y. Ben-Neriah. 2000. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 18:621.
22. Farmer, P., and J. 2000. Pugin. β-adrenergic agonists exert their "anti-inflammatory" effects in monocytic cells through the IκB/NF-κB pathway. Am. J. Physiol. 279:L675.
23. Delgado, M., and D. Ganea. 2000. Inhibition of IFN-γ-induced Janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. J. Immunol. 165:3051.
24. Abbtacchio, M. P., and G. Burnstock. 1998. Purinergic signalling: pathophysiological roles. Jpn. J. Pharmacol. 78:113.
25. + T and B lymphocyte function in vitro and in vivo. Pharmacol Rev. 53:487.
26. Levy, B. D., C. B. Clish, B. Schmidt, K. Gronert, and C. N. Serhan. 2001. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2:612.